Tests SHR-A1811 combinations in recurrent or metastatic cervical cancer
Tests SHR-A1811 with other drugs in adults with recurrent or metastatic cervical cancer.
Plain-language title generated from the registry record
Registry title: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-75 with cervical cancer that has come back or spread. It tests SHR-A1811 combined with other drugs.
- Age
- 18-75 years
- Sex
- Women only
- Disease stage
- Recurrent or metastatic cervical cancer (cancer that has come back or spread).
Main reasons for not taking part
- Previous or current other cancers
- Active or possibly returning autoimmune disease
- Active tuberculosis
- Poorly controlled or severe heart or blood vessel disease
- Serious infection within 1 month before the first dose
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06859775, who can take part
Where in China
- Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT06859775
- Record updated
- 6 June 2025
- Original description
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.Read full original descriptionShow less
Open-label, Multicenter Phase Ib/II Clinical Study of Injectable SHR-A1811 in Combination Regimens for the Treatment of Recurrent or Metastatic Cervical Cancer
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Inclusion: Subjects must voluntarily join this study, sign the informed consent form, have good compliance and be able to cooperate with the follow-up; Female, aged 18-75 years old; Expected survival ≥ 12 weeks; Normal function of vital organs; Female subjects of childbearing potential must have a negative serum HCG test within 7 days prior to the first dose and must be non-lactating; Female subjects must agree to comply with contraceptive requirements from signing the informed consent form to 7 months after the last dose of the investigational drug.
Exclusion: Previous or concomitant other malignancies; Concomitant poorly controlled or severe cardiovascular disease; Occurrence of arteriovenous thrombotic events within 6 months prior to the first dose; Presence of gastrointestinal obstruction or presence of symptoms and signs of gastrointestinal obstruction within 6 months prior to the first dose; Subjects who have had a serious infection within 1 month before the first dose; Presence of active autoimmune disease or history of autoimmune disease with possible recurrence; Those with active tuberculosis; Subjects who have a history of immunodeficiency; Severe bone damage caused by bone metastasis from tumours; As judged by the investigator, there are other factors that may affect the results of the study or cause the study to be forced to terminate halfway.